News | October 10, 2025
Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
The company received seven observations in the Form-483
The company received one observation in the Form-483
The company received 1 (One) observation in the Form-483
TFOS is indicated for the treatment of pulmonary arterial hypertension
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Subscribe To Our Newsletter & Stay Updated
